MangoRx Introduces "MOJO" Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate And Pregnenolone For Treatment Of Low Testosterone And Male Hormone Imbalances; Sold Exclusively On MangoRx's Website On A Subscription Basis At A Price Of $199 Per Month
Portfolio Pulse from Benzinga Newsdesk
Mangoceuticals, Inc. (NASDAQ:MGRX) has introduced a new pharmaceutical product named 'MOJO,' which is a compounded formula featuring Enclomiphene Citrate and Pregnenolone for treating low testosterone and male hormone imbalances. The product will be sold exclusively on MangoRx's website on a subscription basis for $199 per month.
June 04, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mangoceuticals, Inc. (NASDAQ:MGRX) has launched 'MOJO,' a new product aimed at treating low testosterone and male hormone imbalances. The product is sold exclusively on their website for $199 per month.
The introduction of 'MOJO' could positively impact MGRX's revenue by attracting a younger male demographic seeking alternatives to traditional testosterone replacement therapies. The exclusive online sales model and subscription basis may also enhance customer retention and recurring revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100